About Multiple Sclerosis (MS)
- Multiple Sclerosis is a demyelinating disease of the CNS in which the immune system attacks the myelin sheath in the brain and spinal cord.
- Scar tissue forms interfering with the brain’s ability to operate the body.
- There are no curative treatments available today.
What is the MoveS-it Study?
Multiple Sclerosis (MS) Study of ANK-700 to Assess Safety and Immune Tolerance
We are investigating a potential treatment for Relapsing-Remitting MS (RRMS) in a phase 1 clinical study in volunteers with RRMS.
Are you qualified for the MoveS-it study?
- 18 – 60 years old
- RRMS diagnosis
- Not wheelchair bound
- Some medications allowed
If you answered yes to all of these questions use the link below to find out if you can participate.
Other criteria apply.
What is ANK-700?
ANK-700 is an investigational treatment for RRMS. It encompasses a previously identified myelin antigen that is implicated in driving Multiple Sclerosis. We deliver the antigen to the liver and immune system with our liver targeting glycosylation signature.
About Clinical Research
What is clinical research?
Clinical research is the process of developing medicines or therapies to possibly prevent, treat, or help with diseases. Before a medicine can become widely available, it must be tested in a series of clinical trials (sometimes called clinical studies) to understand its safety and effectiveness.
Your safety is the top priority of any clinical trial
Our investigators closely monitor the health of everyone who volunteers for clinical trials and receives study medications. If your health gets significantly worse, your study team will decide the best way to protect your health. This might include leaving the study early.
The phases of clinical research
There are usually three phases of clinical trials that investigational medications must go through before regulatory authorities can consider approving them for wider use. These phases study different aspects about the investigational medications and look at it in different groups of people.
Taking part is voluntary
You do not need to take part in any clinical trial if you don’t want to. Even if you qualify and decide to join, you are free to leave at any time. Just let your study team know so they can do a final health check.
Taking part is at no cost to you
The study medication and all trial-related tests and procedures not considered part of your usual care are normally provided at no cost. If you live in the US, you don’t need insurance to participate. In some locations, transportation to and from study visits or reimbursement for travel-related costs may also be provided, so be sure to ask your study team.
Site Locations
For the MoveS-it Study
UC Health Neurosciences Center
Aurora, CO
PI: Amanda Piquet, MD
Study Contact: Sama Kareem
+1 720.472.2254
UT Health Science Center at Houston
Department of Neurology
Houston, TX
PI: John W. Lindsey, MD
Study Contact: Jim Jemelka
+1 713.500.7045
MS Center of Greater Washington
Vienna, VA
PI: Heidi Crayton, MD
Study Contact: Rebeca Marin
+1 703.226.4030
Cleveland Clinic
Mellan Center for MS
Cleveland, OH
PI: Jeffrey Cohen, MD
Study Contact: Leah Tardivo
+1 216.445.5788
MultiCare Medical Associates
Neuroscience Center of Washington
Tacoma, WA
PI: Stacy Donlon, MD
Study Contact: Tonya Stigger
+1 253.403.1208
Ochsner Clinic Foundation
New Orleans, LA
PI: Jenny Feng, MD
Study Contact: Maya Friedman
+1 504.842.4819
UT Southwestern Medical Center
O’Donnell Brain Institute
Dallas, TX
PI: Benjamin Greenberg, MD
Study Contact: Taylor Quance
+1 214.645.3230
Advanced Neurosciences Institute
Franklin, TN
PI: Samuel F. Hunter, MD, PhD
Study Contact: Samuel Hunter
+1 615.791.5470
Aqualane Clinical Research
Naples, FL
PI: Matthew Baker, MD
Study Contact: Daniela Gonzalez
+1 239.529.6780
Jefferson Hospital for Neuroscience
Comprehensive MS Center
Philadelphia, PA
PI: Thomas P. Leist, MD
Study Contact: Angira Mathur
+1 215.955.5765
University of Kansas
Lander Center on Aging and Neurology
Kansas City, KS
PI: Sharon G. Lynch, MD
Study Contact: Lisa Schmidt
+1 913.588.3968
North Central Neurology
Cullman, AL
PI: Christopher LaGanke, MD
Study Contact: Marla Morris
+1 256.739.1210
Barrow Neurological Institute
Phoenix, AZ
PI: Aimee Borazanci, MD
Study Contact: Mary Thornton
+1 602.406.6287
University of South Florida – Neurology
Tampa, FL
PI: Derrick Robertson, MD
Study Contact: Amber McPherson
+1 813.974.2423
First Care Research Center
Columbia, SC
PI: Eleanya Ogburu-Ogbonnay, MD
Study Contact: Sandra Arinze
+1 855.222.4740
COVID-19 PROCEDURE
We are ensuring that our Phase 1 clinical sites are adhering to national, state, local, and clinical site guidelines during the ongoing COVID-19 pandemic.